Bolla M, de Reijke TM, Van Tienhoven G, Van den Bergh AC, Oddens J, Poortmans PM et al (2009) Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 360(24):2516–2527. https://doi.org/10.1056/NEJMoa0810095

Article  CAS  PubMed  Google Scholar 

Bosland MC (2000) The role of steroid hormones in prostate carcinogenesis. J Natl Cancer Inst Monogr 2(7):39–66. https://doi.org/10.1093/oxfordjournals.jncimonographs.a024244

Article  Google Scholar 

Shaneyfelt T, Husein R, Bubley G, Mantzoros CS (2000) Hormonal predictors of prostate cancer: a meta-analysis. J Clin Oncol 18(4):847–853. https://doi.org/10.1200/JCO.2000.18.4.847

Article  CAS  PubMed  Google Scholar 

Cui Y, Zong H, Yan H, Zhang Y (2014) The effect of testosterone replacement therapy on prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis 17(2):132–143. https://doi.org/10.1038/pcan.2013.60

Article  CAS  PubMed  Google Scholar 

Loeb S, Folkvaljon Y, Damber JE, Alukal J, Lambe M, Stattin P (2017) Testosterone Replacement Therapy and Risk of Favorable and Aggressive Prostate Cancer. J Clin Oncol 35(13):1430–1436. https://doi.org/10.1200/JCO.2016.69.5304

Article  PubMed  PubMed Central  Google Scholar 

Michaud JE, Billups KL, Partin AW (2015) Testosterone and prostate cancer: an evidence-based review of pathogenesis and oncologic risk. Ther Adv Urol 7(6):378–387. https://doi.org/10.1177/1756287215597633

Article  CAS  PubMed  PubMed Central  Google Scholar 

Salonia A, Abdollah F, Capitanio U, Gallina A, Suardi N, Briganti A et al (2013) Preoperative sex steroids are significant predictors of early biochemical recurrence after radical prostatectomy. World J Urol 31(2):275–280. https://doi.org/10.1007/s00345-012-0856-7

Article  CAS  PubMed  Google Scholar 

Neuzillet Y, Raynaud JP, Dreyfus JF, Radulescu C, Rouanne M, Schneider M et al (2019) Aggressiveness of Localized Prostate Cancer: the Key Value of Testosterone Deficiency Evaluated by Both Total and Bioavailable Testosterone: AndroCan Study Results. Horm Cancer 10(1):36–44. https://doi.org/10.1007/s12672-018-0351-8

Article  CAS  PubMed  Google Scholar 

Nascimento B, Miranda EP, Jenkins LC, Benfante N, Schofield EA, Mulhall JP (2019) Testosterone Recovery Profiles After Cessation of Androgen Deprivation Therapy for Prostate Cancer. J Sex Med 16(6):872–879. https://doi.org/10.1016/j.jsxm.2019.03.273

Article  PubMed  PubMed Central  Google Scholar 

Murthy V, Norman AR, Shahidi M, Parker CC, Horwich A, Huddart RA et al (2006) Recovery of serum testosterone after neoadjuvant androgen deprivation therapy and radical radiotherapy in localized prostate cancer. BJU Int 97(3):476–479. https://doi.org/10.1111/j.1464-410X.2006.06013.x

Article  CAS  PubMed  Google Scholar 

Martin NE, Chen MH, Nguyen PL, Beard CJ, Loffredo MJ, Kantoff PW et al (2012) Biopsy Gleason score and the duration of testosterone suppression among men treated with external beam radiation and 6 months of combined androgen blockade. BJU Int 110(9):1252–1256. https://doi.org/10.1111/j.1464-410X.2012.11118.x

Article  PubMed  Google Scholar 

Spiegel DY, Hong JC, Oyekunle T, Waters L, Lee WR, Salama JK et al (2019) A Nomogram for Testosterone Recovery After Combined Androgen Deprivation and Radiation Therapy for Prostate Cancer. Int J Radiat Oncol Biol Phys 103(4):834–842. https://doi.org/10.1016/j.ijrobp.2018.11.007

Article  PubMed  Google Scholar 

D’Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW (2009) Interval to testosterone recovery after hormonal therapy for prostate cancer and risk of death. Int J Radiat Oncol Biol Phys 75(1):10–15. https://doi.org/10.1016/j.ijrobp.2008.10.082

Article  CAS  PubMed  Google Scholar 

McDuff SGR, Chen MH, Renshaw AA, Loffredo MJ, Kantoff PW, D’Amico AV (2018) Impact of time to testosterone rebound and comorbidity on the risk of cause-specific mortality in men with unfavorable-risk prostate cancer. Cancer 124(7):1391–1399. https://doi.org/10.1002/cncr.31217

Article  PubMed  Google Scholar 

Zapatero A, Alvarez A, Guerrero A, Maldonado X, Gonzalez San Segundo C, Cabeza MA et al (2021) Prognostic value of testosterone castration levels following androgen deprivation and high-dose radiotherapy in localized prostate cancer: Results from a phase III trial. Radiother Oncol 160:115–119. https://doi.org/10.1016/j.radonc.2021.04.018

Article  CAS  PubMed  Google Scholar 

Qiu P, Sheng J (2008) A Two-Stage Procedure for Comparing Hazard Rate Functions. Journal of the Royal Statistical Society Series B (Statistical Methodology). 70(1):191–208. https://doi.org/

Li H, Han D, Hou Y, Chen H, Chen Z (2015) Statistical inference methods for two crossing survival curves: a comparison of methods. PLoS ONE 10(1):e116774. https://doi.org/10.1371/journal.pone.0116774

Article  CAS  PubMed  PubMed Central  Google Scholar 

Klein JP, Logan B, Harhoff M, Andersen PK (2007) Analyzing survival curves at a fixed point in time. Stat Med 26(24):4505–4519. https://doi.org/10.1002/sim.2864

Article  MathSciNet  PubMed  Google Scholar 

Hothorn T, Lausen B (2002) Maximally selected rank statistics in R. R News. 2(1):3–5. https://doi.org/

Huggins C, Hodges CV (1972) Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin 22(4):232–240. https://doi.org/10.3322/canjclin.22.4.232

Article  CAS  PubMed  Google Scholar 

Morgentaler A, Traish AM (2009) Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. Eur Urol 55(2):310–320. https://doi.org/10.1016/j.eururo.2008.09.024

Article  PubMed  Google Scholar 

Claps M, Petrelli F, Caffo O, Amoroso V, Roca E, Mosca A et al (2018) Testosterone Levels and Prostate Cancer Prognosis: Systematic Review and Meta-analysis. Clin Genitourin Cancer 16(3):165–175

Article  PubMed  Google Scholar 

Xie W, D’Amico AV (2018) Eighteen Months of Androgen Deprivation Therapy in Men with High-risk Prostate Cancer and the Risk of Death. Eur Urol 74(4):442–443. https://doi.org/10.1016/j.eururo.2018.06.026

Article  PubMed  Google Scholar 

Suzman DL, Antonarakis ES (2015) Does degree of androgen suppression matter in hormone-sensitive prostate cancer? J Clin Oncol 33(10):1098–1100. https://doi.org/10.1200/JCO.2014.60.1419

Article  CAS  PubMed  Google Scholar 

Klotz L, Boccon-Gibod L, Shore ND, Andreou C, Persson BE, Cantor P et al (2008) The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int 102(11):1531–1538. https://doi.org/10.1111/j.1464-410X.2008.08183.x

Article  CAS  PubMed  Google Scholar 

Kishan AU, Sun Y, Hartman H, Pisansky TM, Bolla M, Neven A et al. (2022) Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis. Lancet Oncol. 23(2):304–16. https://doi.org/10.1016/S1470-2045(21)00705-1.

Roach M 3rd, Bae K, Lawton C, Donnelly BJ, Grignon D, Hanks GE et al (2010) Baseline serum testosterone in men treated with androgen deprivation therapy and radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 78(5):1314–1322. https://doi.org/10.1016/j.ijrobp.2009.09.073

Article  CAS  PubMed  PubMed Central  Google Scholar